Mirna Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Mirna Therapeutics, Inc.
- Registration Number
- NCT02862145
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Phase 1
Terminated
- Conditions
- LymphomaNSCLCSCLCRenal Cell CarcinomaPrimary Liver CancerMelanomaMultiple Myeloma
- Interventions
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Mirna Therapeutics, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT01829971
- Locations
- 🇺🇸
Virginia G. Piper Cancer Center, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Texas Oncology Dallas, Dallas, Texas, United States
News
No news found